85 / 86
Characteristic
Liposarcoma
Eribulin
(n = 71)
Dacarbazine
(n = 72)
Total
(n = 143)
Histology subcategory, n (%)
Dedifferentiated
Myxoid/round cell
Pleomorphic
31 (43.7)
29 (40.8)
11 (15.5)
34 (47.2)
26 (36.1)
12 (16.7)
65 (45.4)
55 (38.5)
23 (16.1)
Tumor grade, n (%)
High
Intermediate
Not done
38 (53.5)
32 (45.1)
1 (1.4)
39 (54.2)
32 (44.4)
1 (1.4)
77 (53.8)
64 (44.8)
2 (1.4)
Geographic region
1. United States and Canada
2. Western Europe, Australasia, Israel
3. Eastern Europe, Latin America, Asia
25 (35.2)
36 (50.7)
10 (14.1)
25 (35.2)
37 (51.4)
10 (13.9)
50 (35.0)
73 (51.0)
20 (14.0)
Median age at diagnosis (min, max), y
48 (22, 82)
51 (30, 82)
50 (22, 82)
Previous anticancer therapy, n (%)
0
1
2
3
4
> 4
0
0
37 (52.1)
18 (25.4)
9 (12.7)
7 (9.9)
0
2 (2.8)
33 (45.8)
22 (30.6)
4 (5.6)
11 (15.3)
0
2 (1.4)
70 (49.0)
40 (28.0)
13 (9.1)
18 (12.6)
Chawla SP, et al. Presented at CTOS 2015 Annual Meeting, Salt Lake City, UT, November 4-7, 2015
Study 309 (LPS):
Demographic, Baseline, and Disease Characteristics
(cont)